It’s time the industry spoke out about legal challenge to clinical trial transparency
July 16, 2015Research and Development Richmond Pharmacology, alltrials, clinical trials, health research authority, hra, judicial review, legal challenge, sense about science, transparency
The judicial review brought by Richmond Pharmacology against the Health Research Authority – erroneous, a waste of public money and …
Industry awaits outcome of transparency legal challenge
July 16, 2015Research and Development Richmond Pharmacology, alltrials, clinical trials, health research authority, hra, judicial review, legal challenge, sense about science, transparency
A judge will today hear arguments from the Health Research Authority and campaigners who are contesting a judicial review of …
UK pharma made £41 million in doctor payments
July 16, 2015Medical Communications, Sales and Marketing ABPI, ABPI Code, doctor payments
The pharma industry made £41m in payments to doctors, nurses and other healthcare professionals in the UK in 2014, the …
New Sanofi boss Brandicourt restructures global business
July 16, 2015Sales and Marketing Oliver Brandicourt, Sanofi
Sanofi is reorganising its pharmaceuticals division to create three new business units from January 2016. Chief executive Oliver Brandicourt has …
Janssen sales follow J&J’s downward trend
July 15, 2015Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio
Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …
Celgene to acquire Receptos in $7.2bn deal
July 15, 2015Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis
Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
MRC, GSK and universities team up on inflammatory diseases
July 15, 2015Research and Development COPD, GSK, MRC, Medical Research Council, fibrosis, inflammatory diseases
UK pharma giant GSK is partnering with the Medical Research Council, to study the biological mechanisms behind common inflammatory diseases. …
Ergomed strengthens management team and board
July 15, 2015Research and Development, Sales and Marketing Andrew Mackie, ergomed
UK-based drug development company Ergomed has appointed Andrew Mackie as chief business officer, and to its board as executive director.Mackie …
GSK and the Francis Crick Institute collaborate on drug R&D
July 15, 2015Research and Development Francis Crick Institute, GSK, R&D, The Crick, medical research
The UK’s largest pharma company and the UK’s newest biomedical research facility are partnering up to begin an innovation collaboration.The …
Public Health England and Imperial Innovations boost UK life sciences sector
July 14, 2015Manufacturing and Production, Research and Development Imperial Innovations, Public Health England, R&D, investment, life sciences, spin-puts
The Government has signed-off on the transfer of Public Health England’s drug development and production arm into a state-owned biopharma …
Government launches Accelerated Access Review call to action
July 14, 2015Research and Development Accelerated Access Review, Sir Hugh Taylor, UK, george freeman, john bell, life sciences minister
The Government is urging pharma companies to participate in the Accelerated Access Review, and will launch a website for firms …
FDA approves Lundbeck and Otsuka’s Rexulti for depression
July 14, 2015Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia
Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …
Chancellor announces drug R&D funding boost in Catapult expansion
July 14, 2015Research and Development Cambridge, Catapults, Chancellor, George Osborne, Northern Powerhouse, Precision Medicine, R&D, UK, alderley, economy
Chancellor George Osborne is giving UK drug R&D a £5 million vote of confidence, after promising new investment into two …
Allergan closing manufacturing facility in Iceland
July 14, 2015Manufacturing and Production Actavis, Allergan, Iceland, manufacturing, production, redundancies
Actavis is shutting a plant in Iceland, where its recently-acquired company Actavis has roots, and cutting 300 jobs in the …
Pharma companies look to Apple’s ResearchKit for R&D
July 13, 2015Medical Communications Apple, GSK, Purdue Pharma, R&D, clinical trials, digital health, iOS, iphone, patient engagement, researchkit
Pharma companies are moving into a new area in drug R&D, by using Apple’s ResearchKit platform to gather data from …
Diary of a decade – Ten years in Europe, the Middle East and Africa
July 13, 2015Medical Communications, Sales and Marketing Astellas, Ken Jones
It’s hard to imagine how much a company can change in a decade.When Astellas Pharma Europe was launched 10 years …
Roche posts positive mid-stage trial results for atezolizumab
July 13, 2015Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine
A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …
Novo Nordisk pushes forward with new diabetes drug trial
July 13, 2015Research and Development GLP-1 agonist, Novo Nordisk, diabetes, phase III, semaglutide, type 2 diabetes
Novo Nordisk is taking the first steps towards adding another type 2 diabetes drug to its portfolio, after announcing positive …
NICE recommends Daiichi’s Lixiana for blood clots
July 13, 2015Sales and Marketing DVT, Daiichi, Daiichi Sankyo, Lixiana, NICE, NOACs, VTE, anticoagulant, blood clots, edoxaban, novel anticoagulant. PE
Daiichi Sankyo has won a speedy approval from NICE, after the NHS guidance body approved its newly-launched blood clotting drug …
Pharma dominates global M&A activity
July 10, 2015Sales and Marketing M&A, MA, acquisitions, mergers, takeovers
Mergers and acquisitions in the pharma, medical and biotech sectors have hit the highest levels in nearly 15 years, a …
Latest content
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
